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Mutations or amplification of the MET proto-oncogene are involved in the pathogenesis of 
several tumours1-4, which rely on the constitutive engagement of this pathway for their 
growth and survival1,5. For this reason, many preclinical and clinical studies have tested the 
efficacy of MET inhibition in cancer1,6. However, MET is expressed not only by cancer cells 
but also by tumour-associated stromal cells although its precise role in this compartment is 
not well characterized7-12. Here, we show that MET is required for neutrophil 
chemoattraction and cytotoxicity in response to its ligand HGF. Genetic deletion of Met in 
neutrophils enhances tumour growth and metastasis. This phenotype correlates with reduced 
neutrophil infiltration to both primary tumour and metastatic site. Similarly, Met is necessary 
for neutrophil transudation during colitis, skin rash or peritonitis. Mechanistically, Met is 
induced by tumour-derived TNF-α  or other inflammatory stimuli in both mouse and human 
neutrophils. This induction is instrumental for neutrophil transmigration across an activated 
endothelium and iNOS production upon HGF stimulation. Consequently, HGF/MET-
dependent nitric oxide release by neutrophils promotes cancer cell killing, which abate 
tumour growth and metastasis. Following systemic administration of a MET kinase inhibitor, 
we prove that the therapeutic benefit of MET targeting in cancer cells is partly countered by 
the pro-tumoural effect rising from MET blockade in neutrophils. Our work identifies an 
unprecedented role of MET in neutrophils, suggests a potential “Achilles’ heel” of MET-
targeted therapies in cancer, and supports the rationale for evaluating anti-MET drugs in 
certain inflammatory diseases. 
To ensure specific deletion of Met in the immune system only, we took advantage of the 
Tie2:Cre deleter that excises floxed genes in both bone-marrow (BM) and endothelial cells (EC)13 
and we reconstituted lethally irradiated C57BL/6 wild-type (WT) mice with BM cells from 
Tie2;Metwt/wt (WT) or Tie2;Metlox/lox (KO) mice (Extended Data Fig. 2a), producing WT!WT or 
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KO!WT mice, respectively. When LLC lung carcinoma cells were injected subcutaneously, 
tumour volume, tumour weight, lung metastasis, total metastatic area and metastatic index were all 
higher in KO!WT than in WT!WT mice (Fig. 1a-g). KO!WT mice displayed reduced tumour 
apoptosis and necrosis, but increased proliferation (Extended Data Fig. 2b-n). Tumour vessel area, 
density, perfusion and oxygenation were instead similar in both chimeric mice (Extended Data Fig. 
2o-r). A similar induction in tumour growth and metastasis was observed in non-irradiated KO 
versus WT mice (Extended Data Fig. 2s-u), but WT!KO chimeras displaying deletion of Met in 
EC only showed comparable tumour growth (and vascular features) to those observed in WT!WT 
controls (Extended Data Fig. 2o-r,v). Thus, gene inactivation of Met in immune cells favours cancer 
growth and metastasis. 
Blood counts and percentage of circulating blood cell subsets did not change in WT!WT 
and KO!WT mice, either at baseline or upon LLC tumour engraftment (Extended Data Fig. 3a-e; 
Extended Data Table 1,2). Notably, KO!WT mice displayed reduced numbers of tumour-
infiltrating CD45+ leukocytes (Extended Data Fig. 3f,g) and, among all the different CD45+ 
subpopulations, only Ly6G+ tumour-associated neutrophil (TAN) accumulation was strongly 
reduced in KO!WT versus WT!WT mice at different time points (Fig. 1h-j; Extended Data Fig. 
3f-k). Similarly, lungs from KO!WT tumour-bearing mice contained fewer CD45+ leukocytes 
with decreased Ly6G+ neutrophil infiltration, while macrophages were comparable (Fig. 1k-m; 
Extended Data Fig. 3l,m). Furthermore, reconstitution of Met in neutrophils only14 (Extended Data 
Fig. 4a,b; Supplementary Table 1), was per se sufficient to rescue their recruitment and to hinder 
tumour growth and metastasis in KO!WT mice (Fig. 1n-q). Vice versa, restricted deletion of Met 
in neutrophils (Mrp8;Metlox/lox) by means of the neutrophil-specific Mrp8:Cre line14 (Extended Data 
Fig. 4c,d) recapitulated the accelerated growth and increased lung dissemination of subcutaneous 
LLC tumours observed in KO!WT chimeras, with marked TAN reduction as well (Fig. 1r-u; 
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Extended Data Fig. 4e). These results prove that MET is required for the recruitment of anti-
tumoural neutrophils. 
To extend our findings to other tumour types, we proved that Met deletion in the 
hematopoietic system increased the growth of i) orthotopic T241 fibrosarcomas and B16F10 
melanomas, ii) spontaneous mammary tumours in MMTV-PyMT+ transgenic mice, iii) H-RasG12V 
and c-Myc-driven hepatocellular carcinomas (HCC), and iv) chemically induced colorectal cancers 
(CRC) (Fig. 2a-j; Extended Data Fig. 5a,b). Furthermore, the seeding capacity of B16F10 
melanoma cells to the lungs (from either the primary tumour or after cancer cell intravenous 
injection) and of MMTV-PyMT+ breast tumours was boosted in Met KO chimeras (Fig. 2k,l; 
Extended Data 5c). In all these tumour types, Met KO TANs were fewer than WT TANs (Fig. 2m; 
Extended Data 5d,e). Interestingly, during chronic bowel inflammation, that precedes CRC 
formation, neutrophil but not macrophage infiltration of the colon was also abated by hematopoietic 
Met deletion, but this reduction did not impinge on colitis severity (Extended Data 5f-i). B16F10 
and HCC displayed enhanced tumour growth (and metastasization) as well as reduced TAN 
infiltration in Mrp8;Metlox/lox versus Mrp8;Metwt/wt mice (Fig. 2n-q). Conversely, orthotopic Panc02 
carcinomas grew and metastasized similarly in both WT!WT and KO!WT mice, and TAN 
infiltration did not change (Extended Data Fig. 5j-l). However, these tumours produced very little 
HGF compared to LLC tumours (Extended Data Fig. 5m,n). In general, plasma and intratumour 
HGF did not differ between genotypes (Extended Data Fig. 5o,p). In sum, Met deficiency in 
neutrophils promotes the progression of different (HGF-secreting) tumours.  
Systemic treatment of WT mice carrying B16F10 melanomas (which are highly dependent 
on MET15,16) with three different MET tyrosine-kinase inhibitors (INCB28060, PF-04217903 or 
JNJ-38877605), strongly reduced TAN recruitment (Extended Data Fig. 5q). We then compared 
MET silencing in cancer cells versus systemic MET inhibition (Fig. 2r-t; Extended Data Fig. 5r). 
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PF-04217903 decreased weight and volume of B16F10 melanomas by 36% and 54% respectively, 
whereas MET knockdown in cancer cells by 58% and 75% (Fig. 2r,s). However, the combination of 
these two strategies was not synergic, but, on the contrary, dampened tumour inhibition to the same 
level as observed with PF-04217903 alone (Fig. 2r,s). TAN inhibition by PF-04217903 was 
comparable in both Met-silenced and scramble B16F10 melanomas (Fig. 2t). These data unveil how 
the therapeutic benefit of systemic MET inhibition is partly blunted by the blockade of anti-
tumoural neutrophils. 
To date, MET expression in neutrophils has been poorly documented12. We thus measured 
MET mRNA and protein levels in circulating or tumour-infiltrating neutrophils. Circulating Ly6G+ 
cells from healthy mice expressed low levels of MET, but these levels were increased in circulating 
neutrophils from LLC tumour-bearing mice and even further in TANs (Fig. 3a,b; Extended Data 
Fig. 6a). Similarly, TANs isolated from non-small cell lung cancer patients displayed much higher 
MET levels than neutrophils isolated from healthy pulmonary tissue (Fig. 3c).  
Co-culture with an IL-1α pre-activated endothelium as well as stimulation with tumour- or 
cancer cell-conditioned medium (TCM or CCM, respectively), potently induced MET transcript 
and protein in both mouse and human neutrophils (Fig. 3d-g). Screening for factors known to 
induce MET in other cells17-19, we found that both TNF-α and LPS (but not IL-1α, HGF, or 
hypoxia) promoted MET expression in mouse and human neutrophils (Fig. 3h-k; Extended Data 
Fig. 6b-e; not shown). Particularly, TNF-α-mediated MET induction required TNFR1 and 
subsequent NF-κB activation (Fig. 3i-k). TNF-α alone was not able to trigger either MET 
phosphorylation or HGF release in neutrophils (Extended Data Fig. 6f-h).  
Silencing of EC-borne TNF-α (which is 250-fold increased upon stimulation with IL-1α; 
Extended Data Fig. 6i), genetic knockout of neutrophil-borne TNFR1 (but not of TNFR2), or 
pharmacological blockade of TNF-α with the TNF-α-trap Enbrel, prevented MET induction in 
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mouse or human neutrophils upon co-culture with activated ECs or exposure to TCM/CCM (Fig. 
3l; Extended Data Fig. 6j-m). Finally, systemic administration of Enbrel in LLC tumour-bearing 
mice diminished MET expression in neutrophils as well, resulting in their reduced recruitment to 
the tumour (Fig. 3m,n). Altogether, these data indicate that MET is scarcely expressed in naive 
neutrophils, but strongly induced by inflammatory stimuli. 
Mechanistically, impaired TAN accumulation after Met inactivation was not due to a 
difference in apoptosis as assessed in vivo and in vitro, both at baseline and under LPS stimulation, 
with or without HGF (Extended Data Fig. 7a-e), but rather to a defect in neutrophil recruitment 
from the blood. Indeed, in case of acute inflammation, Met KO neutrophils displayed reduced 
exudation from circulation into the skin or into the peritoneal cavity (Fig. 4a-d; Extended Data Fig. 
8a,b). Macrophage or lymphocyte recruitment did not change (Fig. 4d; Extended Data Fig. 8c,d). 
Vice versa, recombinant HGF was able to recruit Ly6G+ cells inside a subcutaneous air pouch 
induced in WT mice, with similar efficacy of the neutrophil chemoattractant CXCL1 (Fig. 4e; 
Extended Data Fig. 8e). Instead, Met KO neutrophils did not migrate towards HGF, whilst their 
response to CXCL1 was preserved (Fig. 4e; Extended Data Fig. 8e). Mirroring this approach, 
systemic injection of an anti-HGF blocking antibody20 prevented neutrophil infiltration to the 
tumour and to the inflamed skin (Fig. 4f). 
We then tested in vitro the relevance of MET for neutrophil migration. Stimulation of WT 
neutrophils with HGF promoted their adhesion and chemotaxis through an activated endothelium 
whereas Met KO neutrophils (displaying 85% reduction in MET protein levels compared to WT; 
Extended Data Fig. 2a) completely lost this response (Fig. 4g,h; Extended Data Fig. 8f). In line with 
this, TCM (containing 2.6 ± 0.3 ng/ml HGF) promoted transendothelial migration of WT 
neutrophils, but its effect was 43% lower on Met KO neutrophils (Fig. 4i). Upon HGF 
neutralization, WT neutrophils responded to the TCM as Met KO neutrophils (Fig. 4i). HGF or 
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TCM did not influence neutrophil behaviour on non-activated ECs or on bare membranes 
(Extended Data Fig. 8f-h). Hence, HGF-mediated MET activation is required for neutrophil 
transendothelial migration to the inflammatory site.  
Once migrated inside the tumour, N1 or N2 neutrophils can respectively inhibit or favour 
tumour progression21. Amongst the N1 and N2 genes, only the expression of the N1-type marker 
inducible nitric oxide synthase (Nos2, otherwise iNos) was lower in Met KO versus WT TANs but 
similar in macrophages (Fig. 4j; Extended Data Fig. 8i). Compared to WT!WT mice, tumours 
harvested from KO!WT mice displayed reduced nitric oxide (NO) production and 3-nitrotyrosine 
(3NT) formation, a sign of NO-mediated cell damage (Fig. 4k-n). In vitro, Met KO TANs had 
reduced cancer-cell-killing capacity than WT TANs; iNOS inhibition by L-NMMA blunted this 
difference (Fig. 4o; Extended Data Fig. 8j). Consistently, HGF stimulation of WT neutrophils (but 
not of Met KO neutrophils) promoted NO release and cytotoxicity, which was abated by L-NMMA 
(Extended Data Fig. 8k,l).  
We then hypothesized that HGF/MET pathway is key for anti-tumoural neutrophils only.  
Indeed, neutrophil depletion in WT!WT chimeras did not affect significantly the growth of 
subcutaneous LLC tumours, implying that in this tumour model anti-tumoural and pro-tumoural 
neutrophils are in balance (Fig. 4p-r). In contrast, the same treatment in KO!WT mice reduced 
tumour growth by 34% (Fig. 4p-r), indicating that Met deletion inhibits recruitment and activation 
of cytotoxic, but not of pro-tumoural neutrophils, which are instead blocked by the anti-Ly6G 
antibody (Fig. 4r; Extended Data Fig. 8m).  
 In sum, we demonstrate that MET is induced by inflammatory stimuli. This receptor is then 
required for neutrophil extravasation to inflamed tissues. Once in the tissue, neutrophils respond to 
HGF by producing cytotoxic nitric oxide (Extended Data Fig. 1). All these steps restrain non-
specific immune reactions to the inflammatory site and thus prevent the damage of healthy organs. 
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These findings highlight a double-edged role of MET in cancer: on one side, in MET-
addicted tumours, this pathway is vital for cell-cycle and survival2; on the other side, it promotes 
anti-tumourigenic activities in neutrophils. Thus, alternative approaches targeting MET on cancer 
cells only, and trials guided by new patient selection strategies will be important to maximize the 
efficacy of MET inhibition in oncological diseases3,4,22.  
Finally, given the fact that MET-inhibiting drugs are not associated to overt toxicity1,6, 
MET-targeted therapies might be exploited to ameliorate the symptoms of inflammatory disorders 
in which neutrophils are important effectors in the pathogenesis of these diseases23.  
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FIGURE LEGENDS 
Figure 1. Met deficiency inhibits neutrophil recruitment to tumour and metastatic site 
a-g, LLC tumour growth (a), weight (b), lung macrometastases (c), metastatic area (d) with 
representative images of H&E-stained lung sections (e,f), metastatic index (g) in WT!WT and 
KO!WT chimeras. Data combine 3 independent experiments; total mice: WT!WT=23, 
KO!WT=26. h-m, Neutrophil quantification and representative images on Ly6G-stained LLC 
tumour sections (h-j) or on lung sections from tumour-free and tumour-bearing mice (k), the latter 
represented in (l,m). Data in (h) are representative of 4 independent experiments (6-9 
mice/condition per experiment). Data in (k) combine 2-3 independent experiments; total mice: 
Tumour-free=10/condition, Tumour-bearing=15/condition. n-q, LLC tumour growth (n), tumour 
weight (o), lung macrometastases (p), TAN quantification (q) in WT!WT or KO!WT chimeras 
reconstituted with Met in neutrophils only (Mrp8:Met); Mrp8:Empty is used as control. Data 
combine 2 independent experiments; total mice=10/condition. r-u, LLC tumour growth (r), tumour 
weight (s), lung macrometastases (t), TAN quantification (u) upon neutrophil-specific Met deletion 
(Mrp8;Metlox/lox) and controls (Mrp8;Metwt/wt). Data combine 2 independent experiments; total 
mice: Mrp8;Metwt/wt=13, Mrp8;Metlox/lox=14. *, P<0.05 versus WT!WT (a-d,g,h,k), versus 
Mrp8:Empty WT!WT (n-q), versus Mrp8;Metwt/wt (r-u); #, P <0.05 versus Tumour-free (k), 
versus Mrp8:Empty KO!WT (o,q). Scale bars: 100 µm (e,f), 50 µm (i,j,l,m). All graphs show 
mean ± s.e.m.. 
 
Figure 2. Met deficiency in hematopoietic cells fosters progression of several tumour types 
a-c, Tumor growth of T241 fibrosarcomas (a), B16F10 melanomas (b), PyMT-driven spontaneous 
multiple breast cancers (c). Data in (a,b) combine 2 independent experiments; total 
mice=14/condition (a), 8/condition (b). Data in (c) combine 3 independent experiments; total mice: 
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WT!PyMT=13, KO!PyMT=16. d-g, Liver weight (d), nodules (e), and images (f,g) after H-
RasG12V/c-Myc-driven HCC (n=4 mice/condition). h-j, Quantification (h) on H&E-stained bowel 
sections (i,j) of AOM/DSS-induced colon adenomas (yellow arrowheads) or carcinomas (red 
arrowheads). Data combine 2 independent experiments; total mice=10/condition. k, Spontaneous 
lung metastases from B16F10 tumours or lung colonisation after B16F10 intravenous injection. 
Data combine 2 independent experiments; total mice=8/condition. l, Lung macrometastases from 
PyMT tumours. Data combine 3 independent experiments; total mice: WT!PyMT=13, 
KO!PyMT=16. m, TAN quantification in T241, B16F10, PyMT tumours, HCC, and CRC. Data 
combine 1-3 independent experiments; total mice: T241, CRC=10/condition, B16F10=8/condition, 
PyMT=13-16/condition, HCC=4/condition. n,o, B16F10 tumour growth (n), spontaneous 
metastases and lung colonisation (o) in Mrp8;Metwt/wt and Mrp8;Metlox/lox mice. Data combine 2 
independent experiments; total mice: Mrp8;Metwt/wt=12, Mrp8;Metlox/lox=8. p, Liver nodules in 
Mrp8;Metwt/wt and Mrp8;Metlox/lox mice after H-RasG12V/c-Myc-driven HCC. Total 
mice=7/condition. q, TAN quantification in B16F10 tumours (total n: Mrp8;Metwt/wt=12, 
Mrp8;Metlox/lox=8) or HCC (total mice=7/condition). r-t, Tumour growth (r), weight (s) and TANs 
in Met-silenced (shMet) B16F10 tumours after PF-04217903. Data combine 2 independent 
experiments (total mice=11-14/condition). *, P<0.05 versus WT chimeras (a-e,h,k-m), versus 
Mrp8;Metwt/wt (n-q), versus Scramble + Vehicle (r), versus its own Vehicle (s,t); #, P <0.05 versus 
Vehicles (r), versus Scramble (s). Scale bars: 200 µm (i,j), 0.5 cm (f,g). All graphs show mean ± 
s.e.m.. 
 
Figure 3. Met expression in neutrophils is induced by tumour-derived soluble factors 
a-b, qRT-PCR (a) and FACS (b) analysis for MET in blood neutrophils from tumour (TM)-free or 
LLC-tumour-bearing mice and in TANs. c, qRT-PCR for MET in human neutrophils sorted from 
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lung cancer versus healthy tissue. n=4 patients. d,e, MET expression by qRT-PCR (d) or Western 
blot (e) in circulating neutrophils from tumour-free mice after co-culture with unstimulated 
(HUVEC/NS), IL-1α-pre-stimulated HUVEC (HUVEC/IL) or after stimulation with TCM or 
CCM. f,g, qRT-PCR (f) or Western blot (g) for MET in circulating human neutrophils after 
stimulation with A549-CCM. h, Western blot for MET in mouse and human neutrophils after LPS 
or TNF-α stimulation. i, qRT-PCR for Met in WT, TNFR1 KO or TNFR2 KO neutrophils after 
TNF-α stimulation. j,k, qRT-PCR (j) and Western blot (k) for MET in mouse neutrophils after 
TNF-α stimulation with or without NF-κB inhibitor. l, qRT-PCR for Met in mouse neutrophils co-
cultured with HUVEC/IL or stimulated with TCM in presence or absence of the TNF-α trap Enbrel. 
m,n, FACS analysis for MET in TANs (m) and Ly6G+ area (n) in LLC tumours after Enbrel. Data 
combine 2 independent experiments; total mice=5/condition. All data in (a,b,d,f,i,j,l) are 
representative of 2-3 independent experiments using 4-5 biological replicates/condition per 
experiment. All Western blots were repeated 2-3 times on independent biological replicates. 
Western blot full scan images are shown in Supplementary Figure 1. Loading control in (e,h) 
displays tubulin or actin according to Supplementary Figure 1. *, P <0.05 versus TM-free (a,b), 
versus Healthy lung (c), versus Mock (d,f), versus WT (i), versus TNF-α (j), versus IgG (l-n); #, P 
<0.05 versus TM-bearing (a,b), versus Mock (i,l), versus untreated (j). All graphs show mean ± 
s.e.m..  
 
Figure 4. MET is required for neutrophil transendothelial migration and cytotoxicity 
a-c, Neutrophils quantification (a) on TPA-painted ear skin (b,c). Data combine 2 independent 
experiments; total mice=6-9/condition. d, FACS analysis for Ly6G (neutrophils) or F4/80 
(macrophages) on peritoneal lavages after zymosan-induced peritonitis. Representative of 2 
independent experiments using 4-7 mice/condition per experiment. e, FACS analysis for neutrophil 
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recruitment towards HGF or CXCL1 in air pouch assays. Data combine 3 independent experiments; 
total mice=10/condition. f, Ly6G infiltration in LLC tumours or in TPA-painted ear skin after anti-
HGF. Data combine 2 independent experiments; total mice: IgG=11, anti-HGF=6. g-i, Neutrophil 
adhesion to HUVEC/IL (g) and transendothelial migration in response to HGF (h) or TCM with or 
without anti-HGF (i). Representative of 3 independent experiments using 3 biological 
replicates/condition per experiment. j,k, qRT-PCR for Nos2 in LLC-tumour-associated neutrophils 
or macrophages (j) and tumour-derived NO production (k). l-n, Quantification (l) and 
representative images (m,n) of 3NT- (green) and Ly6G- (red) costained LLC tumour sections. Data 
in (j-n) combine 2 independent experiments; total mice=8/condition. o, TAN cytotoxicity against 
LLC cells with or without L-NMMA. Representative of 4 independent experiments using 3 
biological replicates/condition per experiment. p-r, LLC tumour growth (p), weight (r), TANs (r) 
following neutrophil-depleting anti-Ly6G. Data combine 2 independent experiments; total 
mice=16/condition.*, P<0.05 versus WT!WT in the same condition (a,d,e,g-l,o-r), versus IgG (f); 
#, P<0.05 versus Vehicle (a); versus PBS (e), versus Mock (g-i), versus WT!WT untreated (o), 
versus KO!WT IgG (p,q), versus IgG (r); $, P<0.05 versus WT!WT TCM (i). Scale bars: 100 
µm (b,c), 20 µm (m,n). All graphs show mean ± s.e.m..  
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METHODS 
Animals: The Met floxed mice, a gift of Dr. Thorgeirsson (NCI, Bethesda, MD), were backcrossed 
in a C57BL/6 background. The Tie2:Cre and MMTV-PyMT transgenic lines were obtained from 
our mouse facility. The Mrp8:Cre mice were a gift of Dr. Lowell (UCSF, San Francisco, CA) and 
Dr. Bruhns (Pasteur Institute, Paris, FR)14,24-28. C57BL/6 mice were purchased from Harlan. TNFR1 
KO mice and TNFR2 KO mice were a gift of Dr. Libert (VIB, Ghent, BE). The Met floxed mice 
were intercrossed for at least two generations with Tie2:Cre or Mrp8:Cre in order to obtain Metlox/lox 
Cre negative (WT) or Metlox/lox Cre positive (KO) littermates for the specific promoter. All the 
experimental procedures were approved by the Institutional Animal Care and Research Advisory 
Committee of the KU Leuven. In all the experiments, mice were gender and age matched (within an 
age range between 6 and 10 weeks). 
Bone marrow transplantation and blood cell count: Recipient 6-week old female mice were 
lethally irradiated (9.5 Gy) and then intravenously injected with 107 bone marrow (BM) cells from 
WT or KO mice 16 hours later. Experiments were initiated 5 weeks after BM reconstitution. Blood 
cell count was determined using a hemocytometer on peripheral blood collected by retro-orbital 
bleeding.  
Hematopoietic stem/progenitor cell (HSPCs) transduction: For MET overexpression or 
reconstitution in respectively WT or Met KO neutrophils, lineage negative HSPCs were enriched 
with the mouse hematopoietic progenitor enrichment kit (Stem cell technologies) and checked for 
purity by FACS according to the manufacturer’s protocol. 1x106 cells/ml were pre-stimulated for 5 
hours with stem span serum-free medium (Stem Cell Technologies) supplemented with IL-3 (20 
ng/ml), SCF (100 ng/ml) TPO (100 ng/ml) and FLT-3L (100 ng/ml) (Promega) and transduced with 
1x108 TU/ml of a lentiviral vector expressing mouse Met under the promoter of the human gene 
S100A8 (Mrp8:Met), which has been engineered for neutrophil-specific transcriptional targeting, or 
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an empty vector (Mrp8:Empty) as control. Briefly, the promoter driving Met expression in 
neutrophils only, corresponds to a 3.6 Kb DNA fragment encompassing the natural 5’ and 3’ 
regulatory regions but deleted of its exon coding sequences. Hence, Met is under the control of the 
5’ and 3’ untraslated regions of the human S100A8 gene and other proximal cis regulatory 
sequences present in the surrogate DNA fragment14,24-28 . Ten hours after the first viral transduction, 
cells received a second round of their respective lentiviral vector; 7 hours later 1x106 cells were 
injected via tail vein in lethally irradiated C57BL/6 recipient mice. A fraction of transduced HSPCs 
were cultured and collected after 9 days to measure the number of integrated vector copies/cell 
genome (vector copy number, VCN) by qPCR using custom TaqMan assays specific for HIV-gag 
sequences (Applied Biosystems), as previously described29. Standard curves for HIV-gag 
(contained by both Mrp8:Empty and Mrp8:Met lentiviral vectors) were obtained from the 
corresponding plasmids. Fifty ng of genomic DNA from each sample was subjected to qPCR in 
quadruplicate using an ABI Prism 7500 Fast Real-Time PCR System (Applied Biosystems). VCN 
was determined comparing the amplification signal on the genomic DNA with the standard curve 
consisting of serial dilutions over a 6 log range (slope ≈ -3,3, intercept ≈ 35, efficiency % ≈ 100). 
Average copies per cell genome were calculated taking into account that one murine diploid 
genome = 5,92 pg. The results of this analysis are shown in Supplementary Table 1. 
Tumour models: 2x106 LLC or 1x106 B16F10 were injected subcutaneously while 2x106 T241 
cells were injected intradermally in a volume of 200 µl PBS. Tumour volumes were measured 3 
times a week with a calliper. At endstage, tumours were weighed and collected for histological 
examination or FACS analysis. MMTV-PyMT+ spontaneous breast tumours were measured 10 
weeks after birth (6 weeks after BM transplantation), three times a week, and sacrificed at week 16. 
Lung metastases were contrasted by intratracheal injection of a 15% India ink solution, by 
hematoxylin eosin (H&E) staining on lung paraffin sections, or detected by qRT-PCR for the 
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melanoma-specific gene S100B in the models involving B16F10 cells. For orthotopic pancreatic 
tumour growth, mice were anesthetized with isoflurane, the stomach exteriorized via abdominal 
midline incision, and 1x106 Panc02 tumour cells in 30 µl PBS were injected into the head of the 
pancreas using a 29-gauge needle. A successful intrapancreatic injection of tumour cells was 
identified by the appearance of a fluid bleb without intraperitoneal leakage. Mice displaying 
peritoneal leakage were immediately sacrificed and excluded from the analysis. At day 12, primary 
tumours were removed and weighed. Enlarged lymph nodes were counted under a stereoscopic 
microscope. For the chemically-induced colorectal cancer model, body-weight-matched mice 
received one intraperitoneal injection of 10 mg/kg of azoxymethane (AOM) followed by 3 cycles of 
7 days of 1.5% (cycle I) or 1.7% (cycle II-III) dextran sodium sulphate (DSS) in drinking water, 
starting from the day of AOM injection30. After 160 days, the colon was collected and prepared for 
histological evaluation with the “Swiss roll” technique31. For the oncogene-driven hepatocellular 
carcinoma model, mice received a 1:1 molar ratio (3 µg total DNA) of piggyBac transposons 
encoding for c-Myc and H-RasG12V oncogenes, driven by the PGK promoter, together with the 
hyperactive piggyBac transposase-encoding plasmid32. DNA solutions containing 
transposon/transposase plasmids were diluted in 2 ml of Ringer’s solution and hydrodynamically 
delivered in 7 seconds through the tail vein. 
Mice treatments: To induce chronic colitis, mice received 3 cycles of 7 days of 1.5% (cycle I) or 
1.7% (cycle II-III) dextran sodium sulphate (DSS) in drinking water; 2 weeks after the last DSS 
cycle, the colon was collected and prepared for histological evaluation as described above31. For in 
vivo MET inhibition, B16F10 tumour-bearing mice received 40 mg/kg PF-04217903 (AbMole 
Bioscience) or the corresponding vehicle (0.5% methylcellulose in saline) via oral gavage every 
day once a day starting from day 2 after tumour injection and twice a day from day 11 until the end 
of the experiment; alternatively mice were treated with 50 mg/kg INC280 (AbMole Bioscience) or 
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50 mg/kg JNJ-38877605 (Selleckchem). For TNF-α inhibition in vivo, LLC tumour-bearing mice 
were randomized for comparable tumour volumes at the endstage and i.p. injected with 10 mg/kg of 
Enbrel or human IgG in PBS, three and one day before tumour collection. For HGF inhibition in 
vivo, LLC tumour-bearing mice were randomized when average tumour volume was 300 mm3 and 
i.p. injected with 0.2 mg/mouse of anti-HGF blocking antibody (AF-2207, R&D20,33) or goat IgG in 
PBS. Tumours were collected 20 hours later for histological analysis; TPA ear painting was done 5 
hours after antibodies administration and ears were collected 15 hours later. For neutrophil 
depletion, mice were treated with 50 µg/20 g body weight of rat anti-mouse Ly6G antibody (clone 
1A8, BioXCell) or rat IgG every second day starting from day 4 after LLC tumour injection and 
every day from day 12 after tumour injection until the end of the experiment. Efficiency of 
neutrophil depletion was assessed by FACS in blood and tumours. 
TPA model of acute skin inflammation: Phorbol ester TPA was used to induce acute skin 
inflammation as described before34. Briefly, TPA (2.5 µg in 20 µl acetone per mouse) was topically 
applied on the ear skin of anaesthetized mice. The contralateral ear was painted with acetone alone 
as vehicle control. Mice were sacrificed after 24 hours and ears collected in 2% PFA for 
histological analysis. 
Zymosan-mediated acute peritonitis model: To induce acute peritonitis, zymosan A (Sigma) was 
prepared at 2 mg/ml in sterile PBS. Four hours after i.p. injection of 0.1 mg zymosan A per mouse, 
inflammatory exudates were harvested by peritoneal lavage with 2 ml PBS. Cells were counted 
with a Burker chamber and stained for Ly6G (1A8) and F4/80 (BM8) for FACS analysis.  
Air pouch assay: To create subcutaneous air pouches, BM transplanted chimeric mice or 
Mrp8;Metlox/lox or Mrp8;Metwt/wt mice were injected with 3 ml of sterile air by dorsal subcutaneous 
injection with a butterfly 23G needle on day 0 and on day 3. On day 6, 200 ng/mouse of murine 
CXCL1 or HGF dissolved in 0.5 ml PBS-Heparin (15 U/ml) or PBS-Heparin (15 U/ml) as control, 
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were injected in the newly formed dorsal camera. After 4 hours, inflammatory cells were harvested 
by washing the pouch with 5 ml of PBS. Cells were stained for Ly6G (1A8), washed and 
resuspended in PBS 0.1% BSA with unlabelled counting beads and quantified by FACS. 
Mouse blood neutrophil isolation: Blood was collected from the retro-orbital vein in 10% heparin 
and diluted in an equal volume of PBS 0.5% BSA. Up to 5 ml of diluted blood was layered on top 
of a discontinuous gradient of Histopaque 1119 (4 ml) and Histopaque 1077 (5 ml) from Sigma. 
The gradient was centrifuged for 30 minutes at 700g with brake off. The neutrophil layer between 
the Histopaque 1077 and 1119 was collected and washed in PBS 0.5% BSA. RBC lysis was 
performed as in Supplementary Methods. Neutrophils were washed in PBS 0.5% BSA, counted and 
resuspended according to the experimental condition. Alternatively, blood was sedimented in a 
saline solution containing 1.25% dextran and neutrophils were negatively selected with magnetic 
beads35. Neutrophil purity, as assessed by the hemocytometer, was always higher than 93%. 
Bone marrow neutrophil and mononuclear cell isolation: In order to reach reasonable amounts 
of protein, all the Western Blot analyses in mice were performed on neutrophils isolated from bone 
marrows. Mice were sacrificed by cervical dislocation. Femurs and tibias were collected in cold 
sterile Hank Balanced Salt Solution (HBSS, Invitrogen) and flushed with HBSS 0.25% BSA. Cells 
were layered on top of a discontinuous gradient of Percoll 81%, 62%, 55%, freshly prepared and 
centrifuged for 30 minutes at 2000 g with break off. Monocytes were collected at the interface 
between the BM cells and the layer of Percoll 55%, whereas neutrophils were collected at the 
interface between Percoll 55% and 62%. Cells were washed in HBSS 0.25% BSA and RBC lysis 
was performed as described above. Neutrophils (or monocytes) were washed again, counted and 
resuspended according to the experimental setting. Neutrophil (or monocyte) purity assessed by 
hemocytometer was higher than 87%. 
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FACS analysis and flow sorting of blood or tumour-associated cells: Blood was collected in 
10% heparin and stained for 20 minutes at room temperature. After RBC lysis, cells were washed 
and resuspended in FACS buffer (PBS containing 2% FBS and 2 mM EDTA). Tumours were 
minced in RPMI medium containing 0.1% collagenase type I and 0.2% dispase type I (Gibco) for 
30 minutes at 37°C and passed through a 70 and 40 µm cell strainer. After RBC lysis, cells were 
resuspended in FACS buffer and stained for 20 minutes at 4°C. Lungs were collected after 7 
minutes of transcardial perfusion with saline and processed as for the tumours. Briefly, blood or 
single cell suspensions were incubated for 15 minutes at 4°C with Mouse BD Fc Block (2.4G2, BD 
Pharmingen) 1:100 in FACS buffer. The antibodies were added directly in the blocking solution in 
the appropriate combinations (as indicated in the figure legends). CD45 (30F-11), CD11b (M1/70), 
Ly6G (1A8), CD45R (RA3-6B2), CD3 (17A2), CD4 (RM4-5), IgE (R35-72), CD49b (DX5), Ly6C 
(AL-21) (all from BD Pharmingen), F4/80 (BM8), CD115 (AF598), MHCII (M5/114.15-12) (all 
from eBioscience), were used 1:200 for 2x106 in 100 µl; Siglec-F (E50-2440, BD Pharmingen) was 
diluted 1:750. In all the stainings 7AAD (BD Pharmingen) was used to gate out dead cells. For 
intra-tumour proliferation, 1 mg of BrdU was i.p. injected in each mouse 4 hours before tumour 
collection and cell proliferation was quantified on single cell suspensions with the FITC BrdU Flow 
Kit (BD Bioscience) according to manufacturer’s protocol. Tumour apoptosis was assessed by 
staining single cell suspension for the apoptotic marker AnnexinV (1:40, BD Bioscience), 
excluding 7AAD positive cells. For TAN apoptosis, tumour single cell suspensions were gated for 
CD11b (M1/70) and Ly6G (1A8); AnnexinV and 7ADD were used to distinguish apoptotic or dead 
neutrophils. In vitro neutrophil apoptosis was performed by seeding neutrophils isolated from 
tumour-bearing mice at a concentration of 1x106/ml and stimulating them with or without LPS 
(1µg/ml), alone or in combination with HGF (100 ng/ml) for 10 h at 37°C. Cells were collected, 
washed and stained for AnnexinV and 7AAD. The combination of CD11b (M1/70), Ly6G (1A8) 
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and MET (eBioclone 7, eBioscience) was used to identified triple-positive MET expressing 
neutrophils in blood or tumour cells 7AAD-negative. Freshly stained samples were analysed by 
FACS Canto II (BD Bioscience). For tumour-associated neutrophil sorting, myeloid population was 
enriched by coating with CD11b-conjugated magnetic beads (MACS, Miltenyi Biotec) and 
separation through magnetic columns (MACS, Miltenyi Biotec), staining with Ly6G and sorting 
with a FACS Aria I (BD Bioscience). Cells were collected in RLT buffer (Qiagen) for RNA 
extraction or resuspended according to the experimental conditions.  
Western blot: To assess MET deletion, BM cells, neutrophils, peritoneal macrophages, monocytes 
(all cultured overnight in TCM) or endothelial cells were lysed in hot Laemmli buffer (2.5% SDS, 
25% Tris-HCl pH 6.8) for 10 minutes at 96°C, sonicated, cleared and quantified. Alternatively, 
2x106 bone marrow derived neutrophils from WT mice were stimulated with TCM, CCM, 100 
ng/ml of murine TNF-α (or mock medium 0% FBS or 10% FBS as control) for 20 hours at 37°C. 
For the co-culture with HUVEC, a monolayer of HUVEC was stimulated for 4 hours with 5 ng/ml 
IL-1α at 37°C, and washed before neutrophil seeding. After 20 hours of stimulation, neutrophils 
were collected using Cell Dissociation Buffer Enzyme Free PBS-Based (Gibco). Cells were washed 
in PBS, lysed in 15 µl of a protease inhibitor mixture and incubated for 15 minutes on ice. The 
protease inhibitor mixture was obtained by dissolving one tablet of Complete Mini protease 
inhibitor mixture (Roche) in 5 ml of PBS with 2 mM diisopropyl fluorophosphate (DFP; Acros 
Organics, Morris Plains, NJ). After addition of an equal amount of 2x SDS sample buffer 
supplemented with 4% 2-mercaptoethanol, the lysates were boiled for 15 minutes and kept at 
−80°C until use. NF-κB inhibition was achieved by pre-treating 7x106 neutrophils with 10 µM 6-
amino-4-(4-phenoxyphenylethylamino) quinazoline (Calbiochem) for 1 hour at 37°C; cells were 
then stimulated with murine TNF-α (100 ng/ml) for 5 hours before lysis. Human MET was assessed 
by stimulating 3x107 blood neutrophils isolated from the blood of healthy volunteers with A549-
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CCM, 100 ng/ml human TNF-α, 50 ng/ml LPS (or mock medium 10% FBS as control) for 20 
hours. Cells were incubated with 2.7 mM DFP for 15 minutes at 4°C, collected and washed in PBS 
supplemented with 2.7 mM DFP and Complete Mini protease inhibitor 1X, and lysed in hot 
Laemmli buffer at 96°C for 10 minutes. Cell lysates were sonicated, cleared and quantified. 6x 
loading buffer was added before loading on the gel. The following primary antibodies were used: 
mouse anti-mouse Met (3D4, Invitrogen), mouse anti-mouse β-actin (I-19, Santa Cruz), mouse anti-
vinculin (hVIN-1, Sigma), rabbit anti-human Met (D1C2, Cell Signaling), HRP-conjugated anti-
beta-tubulin (Abcam). The following secondary antibodies were used: HRP-conjugated goat anti-
mouse and HRP-conjugated goat anti-rabbit (Santa Cruz). Signal was visualized by Enhanced 
Chemiluminescent Reagents (ECL, Invitrogen) or West Femto by Thermo Scientific according to 
the manufacturer’s instructions. 
Adhesion assay: 4x104 HUVEC were seeded in M199 20% FBS in a 96-multiwell plate, previously 
coated with 0.1% gelatin. After 12 hours, HUVEC were stimulated with 5 ng/ml IL-1α in DMEM 
10% FBS at 37°C. After 4 hours the endothelial monolayer was thoroughly washed and 2.5x105 
WBC isolated indistinctly from Tie2;Metwt/wt and Tie2;Metlox/lox mice or from WT!WT and 
KO!WT transplanted mice, were seeded on top of it, with or without murine HGF (50 ng/ml). 
After 15 minutes non-adherent cells were washed out whereas adherent cells were detached by 
using a Cell Dissociation Buffer Enzyme Free PBS-Based (Gibco). Cells were stained for Ly6G 
(clone 1A8), washed and resuspended in PBS-BSA 0.1% with unlabelled counting beads (BD 
Bioscience) and quantified by FACS Canto II (BD Bioscience). 
Transmigration and migration assay: For the transmigration assay, 2x105 HUVEC were seeded 
on 3 µm polycarbonate membrane (Transwell; Costar) previously coated with 0.1% gelatin in 
M199 20% FBS. After 12 hours, HUVEC were stimulated for 4 hours at 37°C in DMEM 10% FBS 
with 5 ng/ml IL-1α and then washed. 5x105 WBC isolated indistinctly from Tie2;Metwt/wt and 
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Tie2;Metlox/lox mice or from WT!WT and KO!WT transplanted mice were seeded on top of the 
endothelial monolayer, while mock medium, TCM (with or without 3 µg/ml anti-HGF antibody 
AF-2207, R&D33) or 50 ng/ml murine HGF was added in the bottom. After 2 hours at 37°C, 
transmigrated cells were collected from the bottom chambers and from the lower side of the filter 
with cold PBS 0.5% EDTA. Cells were stained and Ly6G+ cells quantified as above. In the 
migration assays WBC were seeded directly on top of 3 µm polycarbonate porous membranes.  
Cytotoxicity assay: LLC shMet or T241 shMet were transduced with a luciferase-expressing 
lentiviral vector (EX-hLUC-Lv114 from GeneCopoeia); 104 cells were then seeded in DMEM 10% 
FBS in a 96-multiwell plate. After 4 hours, 0.2x106 neutrophils purified from the blood of tumour 
bearing mice or directly from the tumours themselves, were co-cultured with the cancer cells in 
DMEM 2% FBS for 4 hours at 37°C, with or without 100 ng/ml mouse HGF or 1 mM L-NMMA 
(Sigma). After washing, adherent cells were lysate in 0.2% Triton, 1 mM DTT. Luciferase signal 
was revealed with a microplate luminometer. The use of shMet was thought to prevent any possible 
confounding activity of MET on cancer cell survival and thus to restrict the effect of HGF to 
neutrophils only. 
Statistics: Data entry and all analyses were performed in a blinded fashion. All statistical analyses 
were performed using GraphPad Prism software. Statistical significance was calculated by two-
tailed unpaired t-test on two experimental conditions or two-way ANOVA when repeated measures 
were compared, with P<0.05 considered statistically significant. Data were tested for normality 
using the D’Agostino-Pearson omnibus test (for n>8) or the Kolmogorov-Smirnov test (for n≤8) 
and variation within each experimental group was assessed. Detection of mathematical outliers was 
performed using the Grubbs’ test in GraphPad. Sample sizes for all experiments were chosen based 
on previous experiences. Independent experiments were pooled and analysed together whenever 
possible as detailed in figure legends. All graphs show mean values ± s.e.m. 
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Extended Data Figure 1. Scheme illustrating the role of MET in neutrophils. 
During cancer or infections, the release of cytokines such as IL-1 at the inflammatory site will 
promote the expression of TNF-a on the endothelium and the surrounding tissue. When circulating 
neutrophils will encounter the activated endothelium, TNF-a will unleash NF-kB through the 
binding to TNFR1, which in turn will induce MET expression on neutrophil surface. HGF, also 
released and proteolytically activated at the site of inflammation, will bind to MET and stimulate 
the firm adhesion of neutrophils to the endothelium, likely via integrin engagement, and thus 
neutrophil diapedesis. Once extravasated, HGF/MET pathway will still function on neutrophils by 
reinforcing their cytotoxic response through the induction of iNOS and NO production, ultimately 
favouring a bactericidal and tumouricidal neutrophil phenotype. 
 
Extended Data Figure 2. Met deletion in immune cells, but not in ECs, fosters tumour growth. 
a, MET expression in total bone marrow (BM) cells, endothelial cells (ECs) and neutrophils 
harvested from Met floxed mice intercrossed with the Tie2:Cre deleter thus generating 
Tie2;Metlox/lox (KO) or  Tie2;Metwt/wt (WT) mice. Western blots are representative of 3 repetitions 
on independent biological replicates. Western blot images have been cropped for presentation. Full 
scan images are shown in Supplementary Figure 1. b-d, Quantification (b) and representative 
images of tumour sections’ TUNEL stainings (c,d) from subcutaneous endstage LLC tumours in 
WT!WT and KO!WT mice. Data combine 2 independent experiments; total n=10 
mice/condition. e, FACS quantification of AnnexinV+ 7AAD- early apoptotic tumour cells in 
WT!WT and KO!WT mice. Data combine 2 independent experiments; total n=8 mice/condition. 
f-j, Tumour necrosis quantification in WT!WT and KO!WT mice (f), assessed by histologic 
evaluation of H&E stained tumour sections (g,h) and by measurement of autofluorescent tumour 
areas (i,j); yellow dotted lines demarcate necrosis. Data combine 2 independent experiments; total 
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n=10 mice/condition. k-m, Quantification (k) and representative images of tumour sections stained 
for the proliferation marker pHH3 (l,m) from subcutaneous endstage LLC tumours in WT!WT 
and KO!WT mice. Data combine 2 independent experiments; total n=10 mice/condition. n, FACS 
quantification of BrdU+ proliferating tumour cells in WT!WT and KO!WT mice. Data combine 
2 independent experiments; total n=10 mice/condition.  o-r, CD31+ vessel area (o), vessel density 
(p), lectin perfusion (q), and hypoxic (Pimo+) area (r) in LLC subcutaneous tumours from 
KO!WT mice (where the hematopoietic/immune system is knocked out for Met) or WT!KO 
mice (where ECs only are knocked out for Met) compared to control WT!WT mice. Data in o-r 
combine 2 independent experiments; total n: WT!WT=12, KO!WT=8, WT!KO=8. s-u, 
Subcutaneous LLC tumour growth (s), weight (t) and lung metastases (u) in Tie2;Metlox/lox 
compared to Tie2;Metwt/wt mice. Data combine 2 independent experiments; total n: 
Tie2;Metwt/wt=12, Tie2;Metlox/lox=10. v, Tumour growth in endothelial cell specific Met KO 
(WT!KO) and control (WT!WT) mice. Data combine 2 independent experiments; total 
n=8/condition. *, P<0.05 versus WT!WT (b,e,f,k,n), versus Tie2;Metwt/wt (s-u). Scale bars: 50 µm 
(c,d,l,m), 100 µm (g-j). All graphs show mean ± s.e.m. 
 
Extended Data Figure 3. Circulating and tumour-infiltrating immune cells upon Met deletion. 
a-e, FACS analysis showing percentages of circulating monocytes (a), lymphocytes (b), neutrophils 
(c), eosinophils (d), and basophils (e) in tumour free or in LLC-tumour bearing WT!WT and 
KO!WT mice. Data combine 2 independent experiments; total n=8 mice/condition. f, 
Quantification of LLC-tumour sections stained for the pan-leukocyte marker CD45, the 
macrophage marker F4/80, the NK marker NK1.1, the B lymphocyte marker CD45R, the T helper 
cell marker CD4, the cytotoxic T cell marker CD8 and the dendritic cell marker CD11c (with 
exclusion of F4/80+ area) in WT!WT and KO!WT mice. Data combine 2 independent 
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experiments; total n=8 mice/condition). g,h, FACS quantification for tumour-associated CD45+ 
leukocytes (g) or CD45+ IgE+ CD49b+ CD4-CD45R- basophils and CD11b+ SiglecF+ Ly6Cmed 
F4/80low MHCII- eosinophils (h) in WT!WT and KO!WT mice. Data combine 2 independent 
experiments; total n=8 mice/condition. i,j, FACS quantification (i) and gating strategy (j) for 
tumour-associated neutrophils selected from the main tumour cell population negative for 7AAD 
staining; tumour-associated neutrophils were then gated as CD11b and Ly6G double positive cells. 
Data combine 2 independent experiments; total n: WT!WT=11, KO!WT=10. k, Ly6G+ tumour 
infiltration at day 9, day 13, and day 19 after LLC subcutaneous tumour injection in WT!WT and 
KO!WT mice. Data combine 2 independent experiments; total n=8 mice/condition. l, 
Morphometric quantification of leukocytes and macrophages on respectively CD45 and F480-
stained lung sections from LLC tumour-bearing WT!WT or KO!WT mice. Data combine 2 
independent experiments; total n=8 mice/condition. m, FACS quantification of CD11b+Ly6G+ 
neutrophils and CD11b+F4/80+ macrophages infiltrating metastatic lungs from LLC tumour-bearing 
WT!WT or KO!WT mice. Data combine 2 independent experiments; total n=8 mice/condition. 
*, P<0.05 versus WT!WT (f,g,i,k-m); #, P<0.05 versus Tumour free (a-d). All graphs show mean 
± s.e.m. 
 
Extended Data Figure 4. MET in neutrophils is required for their anti-tumour activity. 
a,b, Western blot analysis (a) and relative densitometric analysis (b) for MET expression in BM 
neutrophils and monocytes upon reconstitution of WT recipient mice by WT or KO HSPCs 
transduced in vitro with an empty vector (Mrp8:Empty) or a vector expressing Met under the 
neutrophil-specific promoter Mrp8 (Mrp8:Met); tubulin was used as loading control. Western blots 
are representative of 3 repetitions on independent biological samples where each sample is the pool 
of neutrophils or monocytes isolated from 3 mice. Densitometric analysis has been performed on 
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these 3 Western blots. c, FACS analysis for GFP in circulating Ly6G+ neutrophils or CD115+ 
monocytes, harvested from the neutrophil-specific Mrp8:Cre line carrying separate expression of 
GFP because of an Internal Ribosome Entry Site (IRES) downstream the Mrp8-driven Cre gene. 
Data combine 2 independent experiments; total n=10 mice/condition. d, MET expression in 
neutrophils, monocytes, and macrophages harvested from Mrp8;Metwt/wt or Mrp8;Metlox/lox mice. 
Western blots are representative of 3 repetitions on independent biological replicates. e, FACS 
analysis for CD11b+Ly6G+ neutrophils in subcutaneous LLC tumours from Mrp8;Metwt/wt or 
Mrp8;Metlox/lox. Data combine 2 independent experiments; total n: Mrp8;Metwt/wt=10, 
Mrp8;Metlox/lox=11. Western blot images in (a,d) have been cropped for presentation. Full scan 
images are shown in Supplementary Figure 1. *, P<0.05 versus Mrp8:Empty WT!WT (b), versus 
Mrp8;Metwt/wt (e); #, P<0.05 versus Mrp8:Empty WT!WT; $, P<0.05 versus Mrp8:Empty 
KO!WT. All graphs show mean ± s.e.m. 
 
Extended Data Figure 5. Pharmacologic and genetic inhibition of MET prevents the 
recruitment of anti-tumoural neutrophils to several neoplastic tissues and inflammatory sites. 
a, Tumour weight of subcutaneous B16F10 melanomas in WT!WT and KO!WT mice. Data 
combine 2 independent experiments; total n: WT!WT=8, KO!WT=9. b,c, Total tumour weight 
(b) and metastatic index (c) in MMTV-PyMT mice reconstituted with WT or Met KO BM cells 
before tumour appearance (WT!PyMT and KO!PyMT mice, respectively). Data combine 3 
independent experiments; total n: WT!PyMT=13, KO!PyMT=16. d,e, FACS quantification for 
CD11b+Ly6G+ neutrophils in T241 tumours harvested from WT!WT or KO!WT mice (d) or in 
in breast tumours spontaneously grown in WT!PyMT and KO!PyMT mice (e). Data combine 2 
independent experiments; total n=10 mice/condition (d) or total n=8 mice/condition (e). f-i, Length 
measurement (f) and representative image (g) of the colon, as well as quantification of neutrophils 
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(h) and macrophages (i) on bowel sections, from WT!WT and KO!WT mice upon induction of 
chronic colitis compared to healthy control. Data combine 2 independent experiments; total n: 
healthy=5, WT!WT=12, KO!WT=15. j,k, Tumour weight (j) and metastatic mesenteric lymph 
nodes (k) 12 days after orthotopic injection of pancreatic Panc02 cancer cells in WT!WT and 
KO!WT mice. Data combine 2 independent experiments; total n=12/condition. l, Histological 
quantification of Ly6G+ infiltrates in Panc02 pancreatic tumours harvested from WT!WT and 
KO!WT mice. Data combine 2 independent experiments; total n=12 mice/condition. m, 
Quantification of plasma HGF in tumour (TM)-free mice, in subcutaneous LLC or orthotopic 
Panc02 tumour-bearing mice. Data combine 2 independent experiments; total n: TM free=10, 
LLC=10, Panc02=8 biological replicates. n, Quantification of HGF in subcutaneous LLC or 
orthotopic Panc02 tumours. Data combine 2 independent experiments; total n: LLC=10, Panc02=8 
biological replicates. o,p, Quantification of HGF in plasma (o) or in subcutaneous LLC tumours (p) 
from tumour-bearing WT!WT and KO!WT mice. Data are representative of 2 independent 
experiments using 5 mice/condition per experiment. q, Quantification of Ly6G+ area on sections 
from B16F10 melanomas grown in C57BL/6 WT mice, daily treated with PF-04217903, INC280, 
JNJ-38877605, or vehicle as control. Data combine 2 independent experiments; total n: vehicle=14, 
PF-04217903=9, INC280=6, JNJ-38877605=4. r, Western blot analysis for MET in B16F10 
melanoma cells after transduction with a lentiviral vector encoding scramble or mouse shMet under 
a constitutive promoter; vinculin was used as loading control. Western blot is representative of 3 
independent repetitions. Western blot images have been cropped for presentation. Full scan images 
are shown in Supplementary Figure 1. *, P<0.05 versus WT!WT (a,d,h), versus WT!PyMT 
(b,e), versus LLC (m,n), versus Vehicle (q); #, P<0.05 versus Healthy (f,h,i), versus TM free (m). 
Scale bar: 10 mm (g). All graphs show mean ± s.e.m. 
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Extended Data Figure 6. HGF is required for MET activation upon induction by TNF-α . 
a, Gating strategy related to Fig. 3b to quantify MET expression in blood neutrophils from LLC-
tumour (TM)-bearing mice and in TANs, where live cells were first gated as CD11b positive cells; 
this population was finally gated for Ly6G and MET in order to identify MET-expressing Ly6G+ 
neutrophils. b,c, qRT-PCR for MET in mouse (b) and human (c) neutrophils after LPS or TNF-α 
stimulation. Data are representative of 3 independent experiments using 4 biological 
replicates/condition per experiment. d,e, qRT-PCR for MET expression in mouse (b) or human (c) 
neutrophils cultured in normoxia (21% O2) or hypoxia (1% O2). Data combine 2 independent 
experiments; total n=8 biological replicates/conditions per experiment. f,g, ELISA for total MET (f) 
and phospho-MET (g) from mouse neutrophils stimulated for 3 minutes with mock medium or 
HGF after an overnight incubation with or without TNF-α. Data combine 3 independent 
experiments; total n=6 biological replicates/conditions per experiment. h, HGF release by 
neutrophils stimulated with mock medium or TNF-α after 20 hours in culture. Data combine 2 
independent experiments; total n=6 biological replicates/condition per experiment. i, qRT-PCR for 
TNFA in HUVEC upon stimulation with IL-1α compared to mock medium. Data combine 2 
independent experiments; total n=4 biological replicates/condition. j, qRT-PCR for Met in mouse 
neutrophils co-cultured with HUVEC/NS or HUVEC/IL transduced with shTNFA or scramble as 
control. Data are representative of 3 independent experiments where 3 different shRNA sequences 
were used; total n=4 biological replicates/condition per experiment. k,l, qRT-PCR for Met in WT, 
TNFR1, TNRF2 KO neutrophils upon co-culture with HUVEC/NS or HUVEC/IL (k), or after 
stimulation with conditioned medium (TCM) from LLC tumours (l). Data are representative of 2 
independent experiments using 4 biological replicates/condition per experiment. m, qRT-PCR for 
MET in human neutrophils stimulated with A549-CCM in presence or absence of Enbrel or human 
IgGs as control. Data are representative of 2 independent experiments using 4 biological 
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replicates/condition per experiment. *, P<0.05 versus Mock (b,c,i), versus TNF-α alone (g), versus 
HUVEC/NS (j), versus WT (k,l), versus A549-CCM (m); #, P<0.05 versus untreated or HGF alone 
(f,g), versus HUVEC/NS (k), versus Mock (l,m).  Graph shows mean ± s.e.m. 
 
Extended Data Figure 7. Met deletion in neutrophils does not affect apoptosis. 
a,b, Gating strategy of apoptotic WT (a) and Met KO (b) neutrophils in LLC tumours where single 
cells suspensions were firstly gated for physical parameters and then for CD11b and Ly6G in order 
to identify neutrophils as double positive cells; this population was finally gated for AnnexinV and 
7AAD: AnnexinV+ 7AAD- cells display early apoptotic neutrophils whereas AnnexinV+ 7AAD+ 
cells display late apoptotic neutrophils. c, Quantification of apoptotic WT and Met KO tumour-
associated neutrophils measured by FACS. Data combine 2 independent experiments; total n=7 
mice/condition. d, Quantification of apoptotic WT and Met KO neutrophils on LLC tumour 
sections by immunohistochemistry. Data combine 2 independent experiments; total n: WT!WT=7, 
KO!WT=6. e, FACS analysis for AnnexinV and 7AAD of WT or KO neutrophils incubated for 
10 hours in presence or absence of LPS and HGF, alone or in combination. Data combine 2 
independent experiments; total n=6 biological replicates/condition. #, P<0.05 versus untreated or 
HGF alone. Graph shows mean ± s.e.m.  
 
Extended Data Figure 8. MET affects neither neutrophil basal migration nor polarization but 
it is required for neutrophil recruitment and cytotoxicity. 
a, Quantification of Ly6G staining in ear-sections upon phorbol ester (TPA)-induced cutaneous 
rash in Mrp8;Metwt/wt and Mrp8;Metlox/lox mice. Data combine 2 independent experiments; total n=8 
mice/condition. b, FACS analysis on peritoneal lavages for Ly6G+ neutrophils or F4/80+ 
macrophages in Mrp8;Metwt/wt and Mrp8;Metlox/lox mice 4 hours after intra-peritoneal injection of 
           
 33 
sterile zymosan A. Data are representative of 2 independent experiments using 5 mice/condition per 
experiment. c,d, Quantification of F4/80 (c) and CD3 (d) stainings in ear-sections at baseline and 
upon TPA-induced cutaneous rash. Data combine 2 independent experiments; total n: WT→WT 
CTRL=22, KO→WT CTRL=15, WT→WT TPA=23, KO→WT CTRL=15 (c) or total n=8 
mice/condition (d). e, FACS quantification of Mrp8;Metwt/wt and Mrp8;Metlox/lox neutrophils 
recruited into subcutaneous air pouches in response to HGF, CXCL1 or PBS. Data combine 2 
independent experiments; total n=6 mice/condition. f, FACS quantification of WT neutrophil 
adhesion to quiescent HUVEC (HUVEC/NS) or activated HUVEC (HUVEC/IL) in presence or 
absence of HGF. Data are representative of 2 independent experiments using 4 biological 
replicates/condition per experiment. g,h, FACS quantification of WT and Met KO neutrophils 
migrated through a bare porous filter (i.e., in absence of HUVEC) towards HGF (g) or tumour 
conditioned medium (TCM) (h). Data are representative of 2 independent experiments using 3 
biological replicates/condition per experiment. i, Gene expression profile for N1 and N2 markers in 
neutrophils sorted from LLC tumours grown in WT!WT or KO!WT mice. Data are 
representative of 3 independent experiments using 4 mice/condition per experiment. j, Cytotoxicity 
of WT and KO tumour-associated neutrophils against T241 cells in absence or presence of the NO 
synthase inhibitor L-NMMA. Data are representative of 3 independent experiments using 3 
biological replicates/condition per experiment. k, FACS quantification of DAF-FM-positive 
circulating neutrophils after co-culture with LLC cancer cells as a readout of NO production in 
absence or presence of HGF. Data are representative of 4 independent experiments using 3 
biological replicates/condition per experiment. l, Quantification of LLC cancer cell killing by WT 
and KO neutrophils (isolated from the blood of tumour-bearing mice), stimulated with HGF alone 
or in presence of L-NMMA. Data are representative of 2 independent experiments using n=12 
biological replicates/condition per experiment. m, Blood neutrophils in WT!WT and KO!WT 
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mice treated with neutrophil-depleting Ly6G antibody or rat IgG as control. Data combine 2 
independent experiments; total n=16/condition. *, P<0.05 versus Mrp8;Metwt/wt (a,b), versus 
Mrp8;Metwt/wt + HGF (e),  versus HUVEC/NS (f), versus WT!WT untreated (j), versus WT!WT 
HGF (k,l); #, P<0.05 versus CTRL (c,d), versus PBS (e), versus Mock (f,h), versus WT!WT 
untreated (j-l), versus IgG (m); $, P<0.05 versus WT!WT HGF (m). All graphs show mean ± 
s.e.m. 
 
Extended Data Table 1. Blood count in Tie2;Metwt/wt or Tie2;Metlox/lox tumour free mice. 
The values show the hematological parameters (mean ± s.e.m.) in tumour free Tie2;Metwt/wt and 
Tie2;Metlox/lox mice. Data combine 2 independent experiments; total n=10/condition. Abbreviations: 
white blood cell (WBC), neutrophil (NEU), lymphocyte (LYM), monocyte (MON), eosinophil 
(EOS), basophil (BAS), red blood cell (RBC), hematocrit (HCT), mean cell hemoglobin 
concentration (MCHC), platelet (PLT). 
Extended Data Table 2. Blood count in WT!WT and KO!WT tumour free or tumour 
bearing mice.  
The values show the hematological parameters (mean ± s.e.m.) in tumour free or in LLC-tumour 
bearing (21 days) WT!WT and KO!WT chimeric mice. Data combine 2 independent 
experiments; total n=10/condition. Abbreviations: white blood cell (WBC), neutrophil (NEU), 
lymphocyte (LYM), monocyte (MON), eosinophil (EOS), basophil (BAS), red blood cell (RBC), 
hematocrit (HCT), mean cell hemoglobin concentration (MCHC), platelet (PLT). 
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